Severe chest pain plus dynamic ischemic ECG changes in a patient with chronic kidney disease is not merely a troponin problem. Two dangerous errors recur: dismissing myocardial injury as chronic renal disease, or delaying angiography because contrast may worsen kidney function.
Imagine a 74-year-old patient with type 2 diabetes and CKD G3b who develops crushing substernal pressure at rest with nausea, diaphoresis, and dyspnea. The blood pressure is elevated, the heart rate is 106/min, oxygen saturation is borderline on room air, and bibasilar crackles are present. The ECG shows new horizontal ST-segment depression in the lateral precordial leads, high-sensitivity troponin is above the assay’s applicable 99th-percentile upper reference limit, and creatinine is higher than the documented baseline, raising concern for superimposed acute kidney injury.
This is a working diagnosis of suspected high-risk non-ST-segment elevation acute coronary syndrome, not yet a confirmed NSTEMI, possibly complicated by early acute heart failure. The formulation is incomplete until the team obtains serial troponin values, prior ECGs, the creatinine trend, urine output, medication history, bleeding history, body weight for drug dosing, and baseline functional status.
Do not let CKD obscure the ischemic pattern
CKD can produce chronically elevated high-sensitivity troponin, but it does not explain away ischemic symptoms or new dynamic ECG changes. The useful question is not whether the troponin is elevated. It is whether there is acute myocardial injury in an ischemic clinical context.
Under the 2026 Fifth Universal Definition of Myocardial Infarction, acute myocardial injury requires a rise and/or fall in cardiac troponin with at least one value above the assay’s applicable sex-specific 99th-percentile upper reference limit. Myocardial infarction requires acute myocardial injury plus evidence of myocardial ischemia. Thus, a single value above the upper reference limit establishes myocardial injury, but does not by itself establish NSTEMI.
Serial testing matters. A changing troponin pattern, recurrent pain, and evolving ST-T abnormalities carry more diagnostic weight than a single value. If a prior troponin is unavailable, avoid inventing a rigid percentage-change threshold; interpret the result alongside symptoms, ECG findings, echocardiography, and hemodynamics.
| Candidate diagnosis | Findings that support it | Discriminating next step |
|---|---|---|
| Primary MI presenting as NSTEMI | Rest pain, autonomic symptoms, dynamic ST depression, acute rise or fall in troponin with at least one value above the applicable 99th percentile | Treat as high-risk NSTE-ACS while arranging early invasive assessment |
| Chronic myocardial injury in CKD | Previously stable troponin, no ischemic symptoms, unchanged ECG | Compare prior values and ECGs; do not label chronic injury from one result |
| Secondary MI or acute myocardial injury from acute heart failure | Severe anemia, sepsis, tachyarrhythmia, hypertensive crisis, or marked volume stress | Identify and treat the trigger, while using echocardiography and/or angiography as indicated to distinguish secondary MI from primary MI or nonischemic injury |
| Pulmonary embolism or acute aortic syndrome | Pleuritic pain, disproportionate hypoxemia, RV strain, tearing pain, pulse deficit, or neurologic signs | Use targeted imaging and examination before committing to antithrombotic therapy |
The presence of crackles should increase concern rather than reassure. In a patient with ischemic pain, cool extremities, tachycardia, and pulmonary congestion, recurrent ischemia may be impairing left ventricular function even while the blood pressure remains high.
The first hour: stabilize, treat, and mobilize the invasive team
Place the patient on continuous monitoring, obtain repeat ECGs when pain persists or changes, and use bedside echocardiography when immediately available. Echocardiography can identify regional wall-motion abnormalities, reduced ventricular function, right-heart strain, acute mitral regurgitation, or an alternative cause of shock; a nondiagnostic study does not exclude ACS.
Give oxygen for confirmed hypoxemia, generally an oxygen saturation below 90%, or respiratory distress requiring oxygen rather than automatically to every patient with ACS. Nitrates may be useful when blood pressure is elevated and pulmonary congestion is present, provided there is no hypotension or suspected right-ventricular infarction; do not administer them with recent phosphodiesterase-5 inhibitor use, and use caution in severe aortic stenosis. Persistent pain despite initial therapy is a reason to escalate the ACS pathway, not simply to repeat sublingual doses indefinitely.
Unless contraindicated, give a chewable aspirin loading dose. Once ACS is the working diagnosis and major bleeding or aortic concerns have been assessed, add a P2Y12 inhibitor according to the planned invasive strategy, bleeding risk, and likelihood of urgent coronary bypass surgery. When immediate angiography is planned and the coronary anatomy is unknown, routine upstream loading before anatomy is defined may complicate surgery if left-main or multivessel disease is discovered. If angiography is expected to occur more than 24 hours later, upstream clopidogrel or ticagrelor may be considered.
Parenteral anticoagulation is generally part of treatment for definite or strongly suspected NSTE-ACS after major bleeding and alternative diagnoses requiring different therapy have been considered. Renal function should influence the choice. Unfractionated heparin may be attractive when kidney function is changing, urgent PCI is likely, rapid reversal may be needed, or CABG remains possible. If enoxaparin is selected, calculate creatinine clearance using the method specified by the drug label or local protocol rather than assuming that an eGFR of 35 mL/min is equivalent. The labeled severe-renal-impairment threshold is creatinine clearance below 30 mL/min, at which the NSTE-ACS regimen is reduced to once-daily weight-based dosing. At creatinine clearance at or above that threshold, dose reduction is not automatic, but bleeding surveillance remains essential.
CKD changes the dose and the procedural details; it does not erase the ischemic diagnosis.
Why kidney protection should change the technique—not the urgency
Recurrent or refractory angina, acute heart failure or pulmonary edema, hemodynamic instability, or electrical instability should prompt immediate or urgent invasive evaluation. In a stabilized patient, ongoing dynamic ST-segment changes or a steeply rising troponin should prompt early inpatient angiography. A patient with CKD and high-risk ACS should not be managed conservatively solely because contrast-associated kidney injury is feared.
Renal-aware invasive care is practical: use radial access when feasible, minimize contrast volume, avoid unnecessary nephrotoxins, review metformin and other medications according to the patient’s clinical status and current guidance, and monitor creatinine and urine output afterward. Do not give indiscriminate fluid boluses to protect the kidneys in a patient who already has crackles or pulmonary edema. Hydration must be individualized to congestion, perfusion, ventricular function, and urine output.
The same principle applies to revascularization decisions. CKD increases both ischemic and bleeding risk, but it does not automatically favor PCI over CABG or vice versa. Coronary anatomy, lesion complexity, ventricular function, surgical risk, frailty, patient preference, and the likelihood of complete revascularization should be considered by the appropriate multidisciplinary team.
Discharge planning is another risk-stratification exercise
After PCI for ACS, dual antiplatelet therapy is the default for at least 12 months when bleeding risk is not high. Age and CKD increase bleeding risk, but they do not by themselves determine a universal duration. Review prior bleeding, anemia, thrombocytopenia, need for oral anticoagulation, lesion complexity, stent characteristics, and adherence before selecting a shortened strategy. In carefully selected high-bleeding-risk patients, guideline-supported options include earlier transition to single antiplatelet therapy.
Secondary prevention should include a high-intensity statin, blood-pressure management, diabetes optimization, smoking cessation support, and referral to cardiac rehabilitation. An ACE inhibitor or ARB may be appropriate when indicated by hypertension, left-ventricular dysfunction, diabetes, or CKD; check creatinine and potassium after initiation or dose changes. Arrange follow-up for renal recovery, medication reconciliation, and reassessment of functional capacity.
Common traps on rounds and examinations
- CKD explains the high troponin. CKD may cause chronic myocardial injury; do not diagnose NSTEMI from one elevated value or dismiss ischemia when serial change, ECG findings, symptoms, or imaging support ACS.
- No ST elevation means low risk. Dynamic ST depression and recurrent pain can signal an unstable culprit lesion.
- eGFR 35 means enoxaparin must be given once daily. Verify creatinine clearance and the indication-specific label before changing the interval.
- All ACS patients need exactly 12 months of DAPT. Twelve months is the default for many patients, not an inflexible rule for those at high bleeding risk.
- Contrast risk outweighs cardiac risk. In high-risk NSTE-ACS, delaying effective revascularization may be more dangerous than a carefully planned angiogram.
- Crackles call for aggressive fluids. Pulmonary congestion requires hemodynamic reasoning, not reflexive hydration.
Practical takeaways
- Do not diagnose MI from a single elevated troponin. Apply the full pattern: acute troponin rise or fall, the applicable 99th-percentile threshold, symptoms, ECG evolution, examination, and imaging.
- Refractory ischemia, dynamic ECG changes, or acute heart failure should accelerate invasive evaluation.
- Dose antithrombotics using the correct renal metric and indication-specific guidance; eGFR is not automatically interchangeable with creatinine clearance.
- Use radial access, contrast minimization, nephrotoxin avoidance, and individualized fluid management to reduce procedural kidney risk.
- Personalize DAPT duration by balancing ischemic anatomy against bleeding risk rather than applying a fixed rule.
- Before discharge, confirm the creatinine trend, medication plan, functional baseline, rehabilitation pathway, and follow-up testing.